Primary Breast Tumors Often Switch HER2 Status on Relapse Primary Breast Tumors Often Switch HER2 Status on Relapse
A substantial proportion of primary breast tumors switch from HER2-0 to HER2-low expression upon relapse, possibly widening the opportunity to treat patients with novel agents.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 11, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Switch of breast tumors to HER2-low in recurrence may provide greater therapeutic options
(European Society for Medical Oncology) The finding that breast tumours can evolve to express low HER2 potentially widens the number of patients who can benefit from new investigational agents, typically novel antibody-drug conjugate therapies, that are currently in clinical trials for HER2-low tumours. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 8, 2021 Category: Cancer & Oncology Source Type: news
FDA OKs Upfront Pembro for Advanced HER2+ Gastric Cancer FDA OKs Upfront Pembro for Advanced HER2+ Gastric Cancer
The accelerated approval is for first-line use in combination with other agents for locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 6, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
FDA grants accelerated approval to pembrolizumab for HER2-positive gastric cancer
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 5, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Is HER2-Positive Good or Bad?
Title: Is HER2-Positive Good or Bad?Category: Diseases and ConditionsCreated: 5/5/2021 12:00:00 AMLast Editorial Review: 5/5/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - May 5, 2021 Category: Cancer & Oncology Source Type: news
FDA Approves Merck ’s Keytruda (pembrolizumab) Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
KENILWORTH, N.J.--(BUSINESS WIRE) May 5, 2021-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, in... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 5, 2021 Category: Drugs & Pharmacology Source Type: news
Effect of COVID - 19 on Breast Cancer Treatment Examined
More patients with estrogen receptor - positive, HER2 - negative breast cancer treated with neoadjuvant endocrine therapy due to COVID - 19 (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 3, 2021 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Surgery, Conference News, Source Type: news
Xentuzumab/Exemestane/Everolimus in HR+/HER2- Breast Cancer Xentuzumab/Exemestane/Everolimus in HR+/HER2- Breast Cancer
Did patients with locally advanced or metastatic breast cancer realize improvements in progression-free survival after treatment with this triple combination therapy?Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 30, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche ’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer
This study did not meet its primary endpoint of PFS for the initial (first-line) treatment of people with mTNBC in the PD-L1-positive population. As the clinically meaningful benefit demonstrated in the IMpassion130 study remains, Roche looks forward to continuing to work with the FDA to determine next steps with regard to Tecentriq in this indication.Roche remains committed to following the science to better understand cancer, including which patients may benefit most from immunotherapy treatment. Tecentriq has already demonstrated its transformational role in areas of high medical need and is a first in class medicine ap...
Source: Roche Investor Update - April 27, 2021 Category: Pharmaceuticals Source Type: news
US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche ’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer
This study did not meet its primary endpoint of PFS for the initial (first-line) treatment of people with mTNBC in the PD-L1-positive population. As the clinically meaningful benefit demonstrated in the IMpassion130 study remains, Roche looks forward to continuing to work with the FDA to determine next steps with regard to Tecentriq in this indication.Roche remains committed to following the science to better understand cancer, including which patients may benefit most from immunotherapy treatment. Tecentriq has already demonstrated its transformational role in areas of high medical need and is a first in class medicine ap...
Source: Roche Media News - April 27, 2021 Category: Pharmaceuticals Source Type: news
Is HER2 Cancer Aggressive?
Title: Is HER2 Cancer Aggressive?Category: Diseases and ConditionsCreated: 4/26/2021 12:00:00 AMLast Editorial Review: 4/26/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - April 26, 2021 Category: Cancer & Oncology Source Type: news
What Causes HER2 Positive Breast Cancer
What Causes HER2-Positive Breast Cancer? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - April 21, 2021 Category: General Medicine Source Type: news
Can HER2-Positive Breast Cancer Be Cured?
Title: Can HER2-Positive Breast Cancer Be Cured?Category: Diseases and ConditionsCreated: 4/9/2021 12:00:00 AMLast Editorial Review: 4/9/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - April 9, 2021 Category: Cancer & Oncology Source Type: news
'A life-changer': NHS England rolls out five-minute breast cancer treatment
New ‘quicker and kinder’ treatment combining drugs cuts length of time some patients have to spend in hospitalA new breast cancer treatment will cut the amount of time some patients have to spend in hospital from two and a half hours to five minutes.The treatment, called Phesgo, is being rolled out across England by the NHS and will be offered to breast cancer patients undergoing chemotherapy. It will be available to people with HER2-positive breast cancer, which accounts for 15% of all such cancers.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - April 5, 2021 Category: Science Authors: PA Media Tags: Breast cancer NHS Health Society Source Type: news
Is Chemo Necessary for HER2 Positive?
Title: Is Chemo Necessary for HER2 Positive?Category: Diseases and ConditionsCreated: 4/1/2021 12:00:00 AMLast Editorial Review: 4/1/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - April 1, 2021 Category: Cancer & Oncology Source Type: news
